Isavuconazole in treatment of invasive fungal disease in children with malignancy or undergoing cellular therapy.

The letter to the editor discusses the use of Isavuconazole in treating invasive fungal disease in children with malignancy or undergoing cellular therapy. Isavuconazole is a pro-drug rapidly converted to an active drug that inhibits fungal enzyme synthesis. It has high bioavailability and is approved for treating aspergillosis and mucormycosis in adults. The study analyzed the use of Isavuconazole in pediatric hematology and oncology departments in Poland, showing promising outcomes in treating invasive fungal diseases. [Extracted from the article]